Jiangsu Lianhuan Pharmaceutical Co Ltd Net Asset Quality Index
Jiangsu Lianhuan Pharmaceutical Co Ltd net asset quality index. Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has a Net Asset Quality Index of 40.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.16 Billion minus total liabilities of CN¥2.47 Billion yields net assets of CN¥1.69 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
Net asset quality index of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024. This chart shows how Jiangsu Lianhuan Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 25 annual periods from 2000 to 2024. As of March 2026, the index stands at 40.6%, representing net assets of CN¥1.69 Billion against total assets of CN¥4.16 Billion CNY. See 600513 book value for net asset value and shareholders' equity analysis.
Jiangsu Lianhuan Pharmaceutical Co Ltd Net Asset Quality Index by Year (2000–2024)
Jiangsu Lianhuan Pharmaceutical Co Ltd net asset quality index by year from 2000 to 2024. The table below presents the year-by-year Net Asset Quality Index for Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024, covering 25 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 600513 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 52.2% | CN¥1.58 Billion | CN¥3.02 Billion | CN¥1.44 Billion | ▼ -0.9 pp |
| 2023 | 53.1% | CN¥1.52 Billion | CN¥2.86 Billion | CN¥1.34 Billion | ▲ +1.1 pp |
| 2022 | 52.1% | CN¥1.41 Billion | CN¥2.71 Billion | CN¥1.30 Billion | ▼ -2.3 pp |
| 2021 | 54.4% | CN¥1.28 Billion | CN¥2.35 Billion | CN¥1.07 Billion | ▼ -3.3 pp |
| 2020 | 57.7% | CN¥1.18 Billion | CN¥2.05 Billion | CN¥867.05 Million | ▲ +0.3 pp |
| 2019 | 57.4% | CN¥1.08 Billion | CN¥1.89 Billion | CN¥805.57 Million | ▼ -9.3 pp |
| 2018 | 66.7% | CN¥946.61 Million | CN¥1.42 Billion | CN¥473.43 Million | ▼ -8.8 pp |
| 2017 | 75.4% | CN¥878.23 Million | CN¥1.16 Billion | CN¥286.25 Million | ▼ -2.2 pp |
| 2016 | 77.6% | CN¥827.25 Million | CN¥1.07 Billion | CN¥239.03 Million | ▲ +0.1 pp |
| 2015 | 77.4% | CN¥774.88 Million | CN¥1.00 Billion | CN¥225.66 Million | ▲ +11.5 pp |
| 2014 | 65.9% | CN¥434.25 Million | CN¥658.96 Million | CN¥224.71 Million | ▲ +4.0 pp |
| 2013 | 61.9% | CN¥402.11 Million | CN¥649.48 Million | CN¥247.36 Million | ▼ -17.2 pp |
| 2012 | 79.1% | CN¥350.42 Million | CN¥443.21 Million | CN¥92.79 Million | ▲ +0.8 pp |
| 2011 | 78.3% | CN¥327.61 Million | CN¥418.52 Million | CN¥90.91 Million | ▲ +1.2 pp |
| 2010 | 77.0% | CN¥308.95 Million | CN¥401.08 Million | CN¥92.13 Million | ▲ +0.4 pp |
| 2009 | 76.7% | CN¥293.89 Million | CN¥383.36 Million | CN¥89.47 Million | ▼ -1.7 pp |
| 2008 | 78.3% | CN¥281.68 Million | CN¥359.66 Million | CN¥77.98 Million | ▲ +2.8 pp |
| 2007 | 75.5% | CN¥269.97 Million | CN¥357.66 Million | CN¥87.69 Million | ▼ -1.7 pp |
| 2006 | 77.2% | CN¥259.20 Million | CN¥335.84 Million | CN¥76.64 Million | ▼ -6.6 pp |
| 2005 | 83.8% | CN¥255.97 Million | CN¥305.41 Million | CN¥49.44 Million | ▲ +3.6 pp |
| 2004 | 80.2% | CN¥250.42 Million | CN¥312.05 Million | CN¥61.63 Million | ▼ -3.7 pp |
| 2003 | 84.0% | CN¥246.22 Million | CN¥293.21 Million | CN¥46.99 Million | ▲ +16.5 pp |
| 2002 | 67.5% | CN¥85.26 Million | CN¥126.28 Million | CN¥41.02 Million | ▲ +7.4 pp |
| 2001 | 60.1% | CN¥69.48 Million | CN¥115.66 Million | CN¥46.18 Million | ▲ +6.9 pp |
| 2000 | 53.2% | CN¥55.16 Million | CN¥103.67 Million | CN¥48.51 Million | — |